Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Changes in economic institutions and the entrepreneurial climate, together with a growth in venture capital funds, have greatly increased European biotechnology venture formation in recent years.
The current commercial path for nanotechnology ventures mirrors the early evolution of the biotechnology industry, allowing similar strategies toward both technology commercialization and investment opportunities.
Most life science investors have historically shied away from supporting agbiotechnology, but changing consumer acceptance and refinements in infrastructure, intellectual property management and regulations may make the sector more attractive in the coming years.
As the first products based on pharmacogenomics emerge, economic and regulatory considerations will affect—and be affected by—drug approval, licensing and delivery long before medicines are prescribed by a physician.
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.
A survey of US venture capital funds investing in biotechnology shows that the poor economy did not deter VC investment in biotechnology in 2002, but it is unclear what looms ahead.
Because life scientists are now using the Web not only for information gathering, but also for e-commerce, bio-portals business plans are looking more tenable.
Incentives and strategies of key players in the global food industry may be driving public acceptance of agrobiotechnology as much as consumer attitudes.
Robust, reproducible ways to identify and quantify the protein complement of cells are still some way off, as are the means of turning these technologies into viable businesses.
A survey of the scientific and patent literature on single-nucleotide variants reveals the dominance of research centers in the United States and the prolific patenting of SNP technology by a select group of biotechnology companies.